All In MedTech

Device Trial Radar · NCT06158750

To Evaluate the Safety and Effectiveness of Flow Modulation Device for Intracranial Aneurysms

A Prospective, Multicenter, Single Arm Clinical Trial to Evaluate the Safety and Effectiveness of Flow Modulation Device for Intracranial Aneurysms

Last checked: Nov 20, 2026Latest source record: Jun 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

120

Planned (sponsor's estimate)

Start

Nov 17, 2023

Primary completion

Feb 28, 2026

Study completion Jun 30, 2026

Sponsor

Lead sponsor
Shanghai Wallaby Medical Technologies Co.,Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Phenox GmbH; Beijing Wallaby Medical Technologies Co.,Inc.
First posted
Dec 6, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess safety and effectiveness of the p64/p48 MW HPC Flow Modulation Device.

Conditions

  • Intracranial Aneurysm

Interventions

  • p64/p48 MW HPC Flow Modulation DeviceDevice

    Endovascular intervention with p64/p48 MW HPC Flow Modulation Device was performed in patients diagnosed with intracranial aneurysms

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of complete occlusionTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xuanwu Hospital, Capital Medical University

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.